Company news

Arcutis Biotherapeutics, Inc. news in 2020

Arcutis Biotherapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

December 6, 2020

Arcutis to Host Virtual Investor Day on Wednesday, December 9, 2020

December 1, 2020

Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

November 30, 2020

Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis

November 22, 2020

Arcutis Announces Third Quarter 2020 Financial Results and Provides Business Update

November 4, 2020

Arcutis Announces Appointment of Terrie Curran to Board of Directors

November 3, 2020

Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic Dermatitis

November 1, 2020

Arcutis Biotherapeutics to Present New Data from ARQ-151 (Topical Roflumilast Cream) Clinical Program at Three Global Dermatology Conferences

October 28, 2020

Arcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

October 25, 2020

Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock

October 5, 2020

Arcutis Biotherapeutics Announces Pricing of Public Offering and Concurrent Private Placement of Common Stock

September 30, 2020

Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

September 28, 2020

Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

September 15, 2020

Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA

September 7, 2020

Arcutis Announces Second Quarter 2020 Financial Results and Provides Business Update

August 10, 2020

Bethany Dudek Joins Arcutis as Vice President of Quality

August 3, 2020

Arcutis Appoints Patrick Burnett, M.D., Ph.D., FAAD, as Chief Medical Officer

July 26, 2020

Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp Psoriasis

July 19, 2020

Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

July 12, 2020

Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

June 21, 2020

Ayisha Jeter Joins Arcutis as Vice President of Market Access

May 31, 2020

Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and Operations

May 26, 2020

Arcutis Announces First Quarter 2020 Financial Results and Provides Business Update

May 11, 2020

Halley E. Gilbert Appointed to Arcutis Board of Directors

April 26, 2020

Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema

April 20, 2020

Kimberly Lathroum Joins Arcutis as Vice President of Marketing

March 22, 2020

Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis

March 15, 2020

Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate Communications

March 4, 2020

Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual Meeting

March 2, 2020

Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis

February 12, 2020

Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 3, 2020

Decks in 2020